Document Detail

Ovarian cancer stem cells.
MedLine Citation:
PMID:  22862176     Owner:  NLM     Status:  Publisher    
Because of its semi-solid character in dissemination and growth, advanced ovarian cancer with its hundreds of peritoneal tumor nodules and plaques appears to be an excellent in vivo model for studying the cancer stem cell hypothesis. The most important obstacle, however, is to adequately define and isolate these tumor-initiating cells endowed with the properties of anoikis-resistance and unlimited self-renewal. Until now, no universal single marker or marker constellation has been found to faithfully isolate (ovarian) cancer stem cells. As these multipotent cells are known to possess highly elaborated efflux systems for cytotoxic agents, these pump systems have been exploited to outline putative stem cells as a side-population (SP) via dye exclusion analysis. Furthermore, the cells in question have been isolated via flow cytometry on the basis of cell surface markers thought to be characteristic for stem cells.In the Vienna variant of the ovarian cancer cell line A2780 a proof-of-principle model with both a stable SP and a stable ALDH1+ cell population was established. Double staining clearly revealed that both cell fractions were not identical. Of note, A2780V cells were negative for expression of surface markers CD44 and CD117 (c-kit). When cultured on monolayers of healthy human mesothelial cells, green-fluorescence-protein (GFP)-transfected SP of A2780V exhibited spheroid-formation, whereas non-side-population (NSP) developed a spare monolayer growing over the healthy mesothelium. Furthermore, A2780V SP was found to be partially resistant to platinum. However, this resistance could not be explained by over-expression of the "excision repair cross-complementation group 1" (ERCC1) gene, which is essentially involved in the repair of platinated DNA damage. ERCC1 was, nonetheless, over-expressed in A2780V cells grown as spheres under stem cell-selective conditions as compared to adherent monolayers cultured under differentiating conditions. The same was true for the primary ovarian cancer cells B-57.In summary our preliminary investigations indicate that even in multi-passaged cancer cell lines hierarchic government of growth and differentiation is conserved and that the key cancer stem cell population may be composed of small overlapping cell fractions defined by various arbitrary markers. Keywords: ovarian cancer, stem cell, side-population, mesothelium-co-culture, flow cytometry, ERCC1.
A G Zeimet; D Reimer; S Sopper; M Boesch; A Martowicz; J Roessler; A M Wiedemair; H Rumpold; G Untergasser; N Concin; G Hofstetter; E Muller-Holzner; H Fiegl; C Marth; D Wolf; J Hatina
Related Documents :
22397496 - Cisplatin resistance induced by decreased apoptotic activity in non-small-cell lung can...
20010816 - A role for rho gtpases and cell-cell adhesion in single-cell motility in vivo.
6490746 - Control of cellular differentiation by temperature in the cellular slime mould dictyost...
9607196 - Clusterin protects against oxidative stress in vitro through aggregative and nonaggrega...
9194406 - Toxicity of cadmium in human trophoblast cells (jar choriocarcinoma): role of calmoduli...
11431106 - Expression of protease-activated receptor 1 in oral squamous cell carcinoma.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-8-05
Journal Detail:
Title:  Neoplasma     Volume:  -     ISSN:  0028-2685     ISO Abbreviation:  Neoplasma     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-8-6     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0377266     Medline TA:  Neoplasma     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Neuroblastoma stem cells - mechanisms of chemoresistance and histonedeacetylase inhibitors.
Next Document:  Stem cell based glioblastoma gene therapy.